Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...

A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...

Genmab and partner AbbVie (ABBV) are seeing continued good traction of Epkinly, and Genmab says that physicians are providing good feedback since last summer’s approval for relapsed/refractory ...

and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications. Breaking Down Genmab's Financial Performance ...

Company AnnouncementJohnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture ...

Genmab is not under any obligation to update ... Starting with EPKINLY. Together with AbbVie, we continue to advance an ambitious clinical development program for epcoritamab across B-cell ...

and Epkinly (partnered with AbbVie) for the treatment of diffuse large B-cell lymphoma received regulatory approvals in the United States, European Union, and Japan in 2023. We believe Genmab's ...

More than 80% of participants achieved a response, and combining epcoritamab-bysb (Epkinly; Genmab, AbbVie) — a CD3xCD20 bispecific antibody — with gemcitabine plus oxaliplatin (Gem-Ox ...

reflecting investments in Genmab’s pipeline, postlaunch expenses for Epkinly, and profit-sharing commitments to AbbVie related to Epkinly sales. While these investments should contribute to ...

Highlights from Woyach, professor in the division of hematology at The Ohio State University, include a study that evaluated epcoritamab (Epkinly; Genmab, AbbVie) monotherapy, and another that ...